Patient Interview Study to Explore the Impact of Gene Therapy in Hemophilia A & B
Launched by PFIZER · Oct 8, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is designed to understand the experiences of patients with hemophilia A and B who have received gene therapy. The researchers want to learn how this treatment has affected their lives through online interviews. If you have participated in Pfizer's gene therapy clinical studies for hemophilia and have been at least one year post-treatment, you might be eligible to join this study.
Participants will have one visit at the clinic and then take part in an online interview, which will take about 1 to 2 months in total. This study is currently not recruiting participants yet, but it aims to gather valuable insights into how gene therapy impacts the lives of patients with hemophilia. Your experiences could help improve future treatments and support for others living with this condition.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Participation in the Pfizer's gene therapy clinical trials for Hemophilia A or B .
- • Participants will be one year or more post-gene therapy
- • Participants will be willing to provide written consent and will be willing to comply with the study requirements
- Exclusion Criteria:
- • -No exclusion criteria
About Pfizer
Pfizer Inc. is a global leader in biopharmaceutical innovation, dedicated to discovering, developing, and delivering advanced therapies that enhance patient outcomes across a wide range of medical conditions. With a rich history of scientific research and a commitment to quality, Pfizer focuses on areas such as oncology, immunology, cardiology, and rare diseases. The company leverages cutting-edge technology and collaborates with healthcare professionals, regulatory bodies, and academic institutions to conduct rigorous clinical trials that ensure the safety and efficacy of its products. Pfizer's mission is to bring breakthroughs that change patients' lives, exemplifying its commitment to health and wellness worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported